Fiocruz researchers have just released the results of the CovacManaus study, which was conducted over six months in patients with obesity, diabetes, hypertension and immunosuppressed. The objective was to analyze the effectiveness of the vaccine in people with comorbidities, aged between 27 to 70 years and working in the field of education and public health.
- Fiocruz announces delivery of AstraZeneca vaccines this week
- Fiocruz cuts by half its national production estimate. vaccine; understand
In the survey, about
Patient monitoring is still ongoing, according to Marcus Lacerda, study coordinator and researcher at the Instituto Leônidas & Maria Deane. “It is extremely important that each participant attends to collect exams, as scheduled by our call center, so that we can understand the need, for example, for a booster for this vaccine”, he explains.
Want to catch up on the best tech news of the day?
Access and subscribe to our new channel on youtube, Canaltech News.
Every day a summary of the main news of the tech world for you!
Did you like this article?
Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.